L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Published Articles Life Sciences & Pharma Biopharma predictions for 2026: thoughts from LEK Consulting’s Simon Middleton January 14, 2026
Executive Insights Life Sciences & Pharma In Pursuit of Prevalent Disease: Where the Next Mega-Blockbusters Will Be Built January 9, 2026
Smart Chart Life Sciences & Pharma The Race to Lead in Life Sciences Innovation: Lessons from Global Benchmarks December 30, 2025
Published Articles Life Sciences & Pharma The Growth of Radiotherapeutics: Addressing Supply Chain Complexity May 21, 2025
Executive Insights Life Sciences & Pharma Advanced In Vitro Models: Opportunities and Challenges for US Drug Development May 7, 2025
Case Study Life Sciences & Pharma Building Resilience in a Commercial-Stage Pharma Company’s Supply Chain April 16, 2025
